Radioimmunotherapy of lymphoma using anti-CD20 antibodies

  • US 5,843,398 A
  • Filed: 04/26/1996
  • Issued: 12/01/1998
  • Est. Priority Date: 09/16/1993
  • Status: Expired due to Term
First Claim
Patent Images

1. A method for immunotherapy of B-cell lymphoma, which comprises:

  • (i) administering to a patient a clearance-rate-determinative amount of an antibody or a Fab, Fab'"'"' or F(ab'"'"')2 portion thereof trace-labelled with a first radiolabel, which binds to CD20 antigen present on the surface of cells of said B-cell lymphoma;

    (ii) determining the clearance rate of the trace-labelled antibody or the Fab, Fab'"'"' or F(ab'"'"')2 portion thereof of step (i), within the body of the patient;

    (iii) administering to the patient an amount of the antibody or the Fab, Fab'"'"' or F(ab'"'"')2 portion thereof of step (i) in unlabelled form, which binds to CD20 antigen present on the surface of cells of said B-cell lymphoma, said amount effective for blocking non-tumor binding sites for an antibody or a Fab, Fab'"'"' or F(ab'"'"')2 portion thereof effective for treating B-cell lymphoma, within the body of the patient; and

    (iv) administering to the patient a radioimmunotherapeutically effective amount for treating B-cell lymphoma of the antibody or the Fab, Fab'"'"' or F(ab'"'"')2 portion thereof of step (i), which binds to CD20 antigen present on the surface of cells of said B-cell lymphoma, that is labelled with said first radiolabel or with a different radiolabel, wherein the radioimmunotherapeutically effective amount is based on the clearance rate determined in step (ii).

View all claims
    ×
    ×

    Thank you for your feedback

    ×
    ×